Analysts upgrade Bristol Myers to Buy with a $75 target while downgrading Best Buy amid mixed corporate outlooks and earnings trends.
Wall Street analysts adjusted ratings on several major companies, highlighting shifts in earnings expectations and market positioning. Bristol Myers received an upgrade to Buy from Argus, with a $75 price target, citing a turnaround driven by growth products, improved margins, and raised 2026 earnings guidance. Potential M&A interest from AstraZeneca adds to upside catalysts.
McDonald’s was downgraded to Buy from Hold by Freedom Broker, with a revised price target of $305, down from $320. The downgrade follows softer-than-expected revenue and weaker U.S. comparable sales growth. Other notable moves include upgrades for Humana, Expeditors, and Elf Beauty, reflecting improved visibility in Medicare Advantage trends and operational restructuring efforts.
The adjustments reflect broader market sentiment around consumer demand, healthcare cost trends, and corporate restructuring initiatives.